The global anti-thrombin III testing market is expected to grow at a CAGR of 7% during the forecast period of 2024-2032, driven by the increasing shift to rapid diagnostics and rising incidence of thrombotic disorders like venous thromboembolism across the globe.
Base Year
Historical Year
Forecast Year
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Antithrombin III, simply recognised as antithrombin is a protein in the blood that helps manage blood clotting by inhibiting certain enzymes involved in the coagulation process. It is a natural anticoagulant that prevents excessive clotting and helps in balancing the ability of blood to clot and flow freely.
The anti-thrombin deficiency symptoms are similar to the manifestations of other conditions such as antiphospholipid syndrome, deficiency of protein S, and deficiency of protein C. The rising incidence of deficiency-associated illnesses makes it important to have effective anti-thrombin III test kits and systems for hospitals and testing centres. Exact test results can enable medical practitioners to administer reliable treatments for the condition of the patient. As a result, the market value for test kits and devices for anti-thrombin III has increased in recent years. Additionally, a shift towards rapid diagnosis and the emergence of multiple blood clotting disorders will also have a positive impact on the growth of the market.
Increasing Incidence of Thrombotic Disorders Boost Market Growth
According to the data released by the US Centers for Disease Control and Prevention, nearly 900,000 people are estimated to be affected by venous thromboembolism (VTE) each year in the United States. Additionally, the estimated number of total deaths in the U.S. due to venous thromboembolism (VTE) has been estimated to be around 60,000-100,000 people annually. The rising incidence of blood clots and related issues is expected to boost the market growth for anti-thrombin III testing in the forecast period.
Surge in Research Activities to Meet the Rising Anti-Thrombin III Testing Market Demand
In 2023, a research project funded by the European Union’s Horizon 2020 Research and Innovation program successfully developed a mass spectrometry-based test to characterise different molecular forms of antithrombin. This test is anticipated to bring precision to the anti-thrombin III testing as it can be used to explore the clinical relevance of specific antithrombin proteoforms, especially in cases where traditional tests generate ambiguous results. It will generate accurate diagnoses and support medical approaches to develop personalised treatments, propelling the market demand. This also marks a significant milestone in the development of advanced diagnostic tools. Healthcare providers can now adopt new technologies and curb the demand for innovative diagnostic solutions. This innovative diagnostic solution is expected to generate a market demand for more innovations and increase the market value in the forecast period.
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Increasing Prevalence of Blood Clotting Disorders | The rising incidence of conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and other disorders has contributed to the growing demand for antithrombin III testing in the market. |
| Rising Awareness | There is a significant rise in awareness about the early diagnosis of bleeding disorders and management, leading to more routine check-ups of people who may be at risk. This increased awareness is one of the notable market trends, propelling the market demand. |
| Growing Geriatric Population | The rising geriatric population is more prone to thrombotic disorders due to age-related changes in blood coagulation. This trend is contributing to an increased need for antithrombin III testing. |
| Expanding Point-of-Care Testing | There is an increasing preference for point-of-care testing in the market. The development of these testing devices for coagulation parameters including antithrombin III allows for rapid and convenient testing in various healthcare settings such as emergency departments and outpatient clinics. |
Market Breakup by Products
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Anti-Thrombin III Testing Based on Product to Lead the Market Share
The market segment by product is divided into instruments, kits and reagents among others. In the forecast period, the instruments section is estimated to undergo rapid growth, which can be accredited to the advent of new products into the market. Several companies are developing instruments, enabled with automation and precision diagnostics so as to facilitate ease in workflow, efficiency and convenience. On the other hand, kits and reagents hold a substantial market share as healthcare professionals rely on ready-to-use alternatives for immediate testing.
Anti-Thrombin III Testing Market Analysis by Region
Based on region, the market is divided into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America is significantly dominating the market. The region is leading due to its high-tech healthcare infrastructure integrated with advanced technologies and world-class facilities. It is also witnessing a relatively high prevalence of conditions associated with blood clotting disorders, such as deep vein thrombosis, contributing to the increasing demand for comprehensive diagnostic testing, supporting the dominance of the region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
F. Hoffmann-La Roche Ltd
Commonly known as Roche, it is a Swiss multinational healthcare company operating in pharmaceuticals and diagnostics. It is the fifth-largest pharmaceutical company in the world by revenue specialising in providing treatments for cancer globally.
Siemens Healthineers AG
It is a German multinational company focused on providing innovative healthcare solutions through advanced technologies and services. The company offers a comprehensive range of diagnostic solutions, including clinical chemistry, immunoassays, hematology, and molecular diagnostics.
Abbott Laboratories
It is an American multinational company that develops and sells medical devices and healthcare products. The company is a global leader in diagnostic solutions and offers advanced laboratory systems and point-of-care testing products. Their diagnostics division includes immunoassays, clinical chemistry, hematology, and molecular diagnostics.
Beckman Coulter, Inc. (A Danaher Company)
It is a Danaher Corporation company focused on developing, manufacturing, and marketing laboratory instruments and reagents used in biomedical testing. Their product portfolio includes immunoassay systems, hematology analyzers, clinical chemistry analyzers, and automation solutions.
Thermo Fisher Scientific Inc.
Thermo Fisher is a life science and clinical research company that develops diagnostic tests and instruments, used in clinical and industrial settings, like immunoassays, microbiology, and molecular diagnostics.
Other key players in the market include Sysmex Corporation, Horiba Abx SAS, bioMerieux SA, and HemoSonics, LLC, among others.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The global market of anti-thrombin III testing is projected to grow at a CAGR of 7% between 2024 and 2032.
The major drivers of the industry, such as the rising need for rapid diagnosis and the emergence of multiple blood clotting disorders, are expected to aid the market growth.
The key market trend guiding the industry growth includes the launch of new anti-thrombin III testing methods.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Hospitals, laboratories, and academic and research institutes are the leading end uses of the product in the industry.
The major players in the industry are F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc., among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share